CAMBRIDGE, Mass., Sept. 8, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will participate in the following virtual investor conferences in September.
- Citi's 15th Annual BioPharma Conference
John P. Butler, President and Chief Executive Officer, to participate in virtual one-on-one meetings on Wednesday, September 9.
- H.C. Wainwright 22nd Annual Global Investment Conference
Michel Dahan, Chief Operating Officer, and David Spellman, Chief Financial Officer, to participate in a virtual fireside chat on Monday, September 14, at 10:00 a.m. ET.
- Morgan Stanley Virtual 18th Annual Global Healthcare Conference
John P. Butler, President and Chief Executive Officer, to participate in a fireside chat on Tuesday, September 15, at 1:15 p.m. ET.
- Cantor Virtual Global Healthcare Conference
John P. Butler, President and Chief Executive Officer, to present on Wednesday, September 16, at 1:20 p.m. ET.
Where applicable, live webcasts of Akebia's presentations will be made available on the Investors section on the Company's website at https://ir.akebia.com.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Kristen K. Sheppard, Esq.
View original content to download multimedia:http://www.prnewswire.com/news-releases/akebia-therapeutics-announces-september-2020-investor-conference-schedule-301125188.html
SOURCE Akebia Therapeutics